Mycoplasma fermentans Inhibits the Activity of Cellular DNA Topoisomerase I by Activation of PARP1 and Alters the Efficacy of Its Anti-Cancer Inhibitor

Reuven Afriat, Shulamith Horowitz, Esther Priel*

The Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, and the Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel

Abstract

To understand the effects of the interaction between Mycoplasma and cells on the host cellular function, it is important to elucidate the influences of infection of cells with Mycoplasma on nuclear enzymes such as DNA Topoisomerase type I (Topo I). Human Topo I participates in DNA transaction processes and is the target of anti-cancer drugs, the camptothecins (CPTs). Here we investigated the mechanism by which infection of human tumor cells with Mycoplasma affects the activity and expression of cellular Topo I, and the anti-cancer efficacy of CPT. Human cancer cells were infected or treated with live or sonicated Mycoplasma and the activity and expression of Topo I was determined. Mycoplasma significantly reduced (by 80%) Topo I activity in the infected/treated tumor cells without affecting the level of Topo I protein. We demonstrate that this reduction in enzyme activity resulted from ADP-ribosylation of the Topo I protein by Poly-ADP-ribose polymerase (PARP-1). In addition, pERK was activated as a result of the induction of the MAPK signal transduction pathway by Mycoplasma. Since PARP-1 was shown to be activated by pERK, we concluded that Mycoplasma modified the cellular Topo I activity by activation of PARP-1 via the induction of the MAPK signal transduction pathway. Moreover, the infection of tumor cells with Mycoplasma diminished the inhibitory effect of CPT. The results of this study suggest that modification of Topo I activity by Mycoplasma may alter cellular gene expression and the response of tumor cells to Topo I inhibitors, influencing the anti-cancer capacity of Topo I antagonists.

Introduction

Mycoplasmas, which belong to the Mollicutes class, are the smallest self-replicating eubacteria, devoid of a cell wall and surrounded only by a plasma membrane. Their small genome size (ranging from 580 to 1380 kbp) results in limited metabolic capabilities and parasitism [1,2]. Mycoplasmas can be found as parasites in a wide range of hosts including humans, animals, insects, plants, and cells grown in tissue culture.

In humans, some Mycoplasma species are found as commensal inhabitants, while other were shown to be associated with infectious diseases and post-infection pathologies [3,4].

Most of the known Mycoplasma species are found as membrane surface parasites, and recently, some were shown to enter the cells and become intracellular residents [5].

Mycoplasma may cause chronic infections due to sophisticated mechanisms for evasion from immune surveillance (i.e., molecular mimicry, a unique type of antigenic variation), up-regulating or down-regulating cytokine secretion, adhesion molecules expression, transcription factors expression, MAP kinases activity, apoptotic pathways, and more [2,3].

Recently, many reports have strongly supported the ability of Mycoplasma to cause or promote oncogenic transformation [6–9], and the search for the link between Mycoplasma and cancer is currently being explored [10].

The lipoproteins (LPMf) of Mycoplasma fermentans, a human pathogen, was thoroughly investigated during the last decade. LPMf was shown to alter the functions of the immune system cells by inducing expression of oncogenes [1], affecting several factors participating in signal transduction proteins [11–13], transcription [14], and the apoptotic process [11,15,16]. Mycoplasma was shown to inhibit the apoptosis process induced by tumor necrosis factor α (TNFα) [17,18]. All these led to the assumption that infection of tumor cells by Mycoplasma may affect the activity and expression of essential nuclear enzymes such as topoisomerases, which are the targets of several anti-cancer drugs and thus interfere with the anti-cancer efficacy of these drugs. DNA topoisomerases are a family of essential nuclear enzymes that are responsible for controlling the topological state of the DNA molecules. They participate in most DNA transactions such as replication, transcription, recombination, and chromatin remodeling [19–21]. DNA topoisomerases are classified as either type I (cleaves one strand of DNA) or type II (cleaves two strands of DNA). Both enzyme types are further categorized into subgroups according to structural and functional features. Members of each
family of enzymes are distinct in sequence, structure, and functions [22].

The catalytic activity of DNA topoisomerases involves the formation of transient covalent bridges of enzyme-DNA complexes. A tyrosyl group in the active site of the enzyme attacks a phosphodiester bond on the DNA backbone and remains covalently attached to one side of the break, leaving an opposite free hydroxyl (OH) end that allows the religation step, after DNA topology is resolved, by a second nucleophilic attack of the covalent enzyme-DNA phosphotyrosine bond, releasing the enzyme for the next catalytic cycle. The involvement of these enzymes in essential cellular processes tagged topoisomerases as important targets for anti-cancer treatments and for the development of potent, more effective, anticancer drugs [22,23]. The cytotoxicity of Topoisomerases inhibitors such as Camptothecin (CPT) and its derivatives TPT and CPT-11 (which are approved for clinical use), stems from their ability to stabilize the cleavable complex of Topo–DNA, which introduces single and double strand breaks in the DNA [21,24,25]. Topoisomerase activity is influenced by several post-translational modifications, among them phosphorylation, poly-ADP-ribosylation, and ubiquitination. Recent work done in our laboratory demonstrated the O-GlcNAcylation of Topo IB, which affects its activity [26].

The phosphorylation of DNA topoisomerase I by casein kinase II (CK II) and protein kinase C (PKC) up-regulate the enzyme DNA relaxation activity, whereas dephosphorylation by alkaline phosphatase inhibited this activity. In addition, poly-ADP-ribosylation by poly-ADP ribose polymerase (PARP-1) of the enzyme protein was found to down-regulate its activity [20,27]. PARP-1 is known to be activated by DNA breaks; however recently, it was reported that PARP-1 can be activated by phosphorylated ERK2 in the absence of stress conditions or DNA damage [26].

Materials and Methods

Cells

Human breast cancer cell lines MCF7 (American Type Culture Collection, HTB-22) and human glioblastoma cells U251 (HTB-17) kindly received from Porgador A, Ben-Gurion University. Cells were cultured as monolayers in DMEM and RPMI 1640 medium (Biological Industries, Beit Haemek, Israel), respectively, supplemented with 10% fetal bovine serum, 50 IU penicillin, 50 μg/ml streptomycin, and L-glutamine (0.29 mM). Cell lines were grown in a humidified incubator supplemented with 5% CO₂ at 37°C.

Enzymes, Antibodies, and Compounds

Stock solutions of Camptothecin (Sigma, Israel) at 20 mM (dissolved in 100% DMSO) were stored in aliquots at -70°C and diluted in DMSO before being added to the reaction mixture or to the cell culture medium. Supercoiled DNA plasmid pUC19 was purchased from MBI Fermentas (Hanover, MD, USA). PD98059 and 3-aminobenzamide (3AB) were purchased from Sigma-Aldrich (Rehovot, Israel).

The primary antisera were as follows: monoclonal mouse anti-β-actin antibody (MP Biomedicals, LLC); goat polyclonal IgG (C-15) anti-topo I, mouse monoclonal IgG antiphospho-ERK (E-4), and rabbit polyclonal IgG anti-ERK (C-16) (Santa Cruz Biotechnology Inc., CA, USA); mouse monoclonal anti-poly-ADP ribose

Figure 1. Infection of cells with live M. fermentans inhibits the DNA relaxation activity of Topo I. MCF7 (A,B) and U251 (C,D) cancer cells were infected with live M. fermentans (M.f) for various intervals at MOI of 10³ CFU/cell. Total nuclear protein (12.5 ng) was added to a specific reaction mixture for Topo I. Reaction products were analyzed by agarose gel electrophoresis. (A,C) A representative picture (n = 4–5) of Topo I DNA-relaxation activity. (B,D) Quantification analysis of Topo I activity. Symbols: R and S are the relaxed and supercoiled form of the pUC19 DNA, respectively; Topo-no protein added to the reaction mixture. t-test: *p<0.05, **p<0.01, ***p<0.005.

doi:10.1371/journal.pone.0072377.g001
antibodies, (Serotec, Oxford, UK); and goat anti-mouse and anti-rabbit IgG second antibodies (Biolabs Inc., Ipswich, MA, USA). For immunoprecipitation assays, anti-Topo I antibody derived from scleroderma patient serum was used (TopoGene, Florida, USA).

Enhanced chemiluminescence (ECL) reagents were purchased from Biological Industries (Beit Haemek, Israel).

Mycoplasma Growth

*M. fermentans* strain K7 was cultured in SP4 broth at 37°C and 5% CO2 until log phase. One ml aliquots containing $2 \times 10^8$ colony-forming units (CFU) were kept frozen at −70°C until used. For each experiment, one aliquot was thawed, cultivated in SP4 broth at a dilution of 1/10 for 24 h (37°C, 5% CO2), followed by further dilution of 1/50 until a log phase was observed (after approx. 24 hrs). The exact quantity of *M. fermentans* was determined by counting CFUs, as previously described [32,33].

Figure 2. Infection of cells with live *M. fermentans* (M.f) did not alter the level of Topo I protein. Samples from the MCF7 and U251 infected cells (described in Figure 1) were analyzed for detection of mycoplasmal DNA by PCR (A,B). Nuclear extracts derived from MCF7 and U-251 infected cells were assayed for Topo I protein level using Western blot analysis with anti-Topo I or anti-β-actin antibodies, and quantified by densitometric analysis using the EZquant software (C–F).

doi:10.1371/journal.pone.0072377.g002

Figure 3. Sonicated *M. fermentans* Protein inhibits the DNA relaxation activity of Topo I. MCF7 (A–C) and U251 (D–F) cancer cells were treated for 24 hrs with various concentrations of *M. fermentans* proteins. Total nuclear proteins (12.5 ng) were added to a specific reaction mixture for Topo I. Reaction products were analyzed by agarose gel electrophoresis. (A,D) A representative picture (n = 4–5) of Topo I DNA relaxation activity. (B,E) Quantification analysis of Topo I activity. (C,F) Topo I protein level examined by Western blot analysis. Symbols: R and S are the relaxed and supercoiled form of the pUC19 DNA, respectively, Topo- no protein added to the reaction mixture. t-test: *p<0.05, **p<0.01, ***p<0.005.

doi:10.1371/journal.pone.0072377.g003
Mycoplasmal Protein Extract Preparation

*M. fermentans* was cultivated as above; the 500 ml culture was pelleted (13000 g, 30 min at 4°C) and washed twice with phosphate-buffered saline (PBS). The pellet was then re-suspended in PBS. CFU/ml was determined, and the re-suspended pellet was stored at 270°C for further experiments. Frozen pellets of *M. fermentans* were thawed and sonicated at 4°C for 4.6-30 sec at 80% power (50% duty cycle; Heat Systems Ultrasonics, Inc.) in the presence of the protease inhibitor phenylmethylsulphonyl fluoride (PMSF; 0.001 M). These conditions of sonication resulted in a non-live mycoplasmal preparation (no growth was observed in repeated culturing procedures). Protein concentration of the sonicated *M. fermentans* was determined by the Bio-Rad protein assay kit (Richmond, CA); 1×10^8 CFU corresponded to 10 μg mycoplasmal protein.

DNA Amplification of *M. fermentans* by Reverse Transcription-PCR (RT-PCR) Using a Nucleotide Sequence within the Insertion Sequence-Like Element

Total RNA was extracted from the infected MCF7 and U251 cells using TRI Reagent (T9424; Sigma-Aldrich, Rehovot, Israel), then reverse transcribed using 1 μg of total RNA from the examined cells with Oligo-dT primer, using RevertAid Kit (K1621; Fermentas, Vilnius, Lithuania). Various cDNA isolated from *M. fermentans*-infected cells for different intervals (1.5, 3, 6, 12, and 24 hrs) were amplified using REDTaq Ready Mix (R2523; Sigma-Aldrich, Rehovot, Israel). Sequences of the synthetic oligonucleotide primer pair (RWO04 and RWO05) used for specific DNA amplification of *M. fermentans* and their positions in the Insertion Sequence-Like Element (IS-like element) were previously described [34]. The primer sequences and sizes of the PCR products were as follows: RW004 Primer (24 nt): 5’GGA CTA TTG TCT AAA GAA TTC TCC and RW005 Primer (24 nt): 5’GGT TAT TCG ATT TCT AAA TCG CCT. The size of the diagnostic DNA band is 206 bp. The thermal cycling profile of amplification comprised 40 cycles at 95°C for 30 seconds (240 seconds in the first cycle), 62°C for 60 seconds, and 72°C for 60 seconds (increased to 10 minutes for the final cycle). The PCR products were visualized on a 1% agarose gel stained with ethidium bromide.

Treatment of Malignant Cell Lines with Live *M. fermentans* or *M. fermentans* Total Protein

MCF7 and U251 cells, prewashed once with PBS (1200 RPM, 5 min at 4°C) and re-suspended in a new culture medium at a concentration of 2×10^5 cells/ml, were cultured in 96-well sterile plates (Corning Inc., Corning, NY) at a final concentration of 4×10^4/200 μl/well. Live *M. fermentans* at log phase, prewashed once in PBS (13000 xg, 30 min at 4°C), and re-suspended in RPMI 1640 medium containing 10% inactivated FCS, 1% penicillin, and 1% glutamine, were added to the cell cultures at MOI 1000:1 (4×10^7 CFU/well). The co-cultures were incubated for five hrs at 37°C, 5% CO₂. For experiments with *M. fermentans* total protein, a concentration of 20 μg/ml (corresponding to 2×10^8 CFU) was added to the examined tumor cells (2×10^5 cells/ml) for 24 hrs at 37°C, 5% CO₂.

**Figure 4.** *M. fermentans* diminished the CPT inhibition effect on the DNA relaxation activity of Topo I. MCF7 cells were infected with *M. fermentans* (M.f) for 6 hrs followed by CPT (30 μM) treatments for additional 1.5 hrs. Total nuclear protein (12.5 ng) was added to a specific reaction mixture for Topo I. Reaction products were analyzed by agarose gel electrophoresis. (A) A representative picture n = 5, of Topo I DNA-relaxation activity. (B) Quantification analysis of Topo I activity. (C) Topo I protein level examined by Western blot analysis. Symbols: R and S are the relaxed and supercoiled form of the pUC19 DNA, respectively, Topo- no protein added to the reaction mixture t-test: *p<0.05, **p<0.01, ***p<0.005.

doi:10.1371/journal.pone.0072377.g004
Modification of Topoisomerase I by *M. fermentans*

**Nuclear Protein Extracts Preparation**

Nuclear extracts for Topoisomerase assays and Western blot analysis from the MCF7 and U251 cells were prepared as previously described [27,33–40] and a mixture of protease inhibitors (final concentration: 1 mM Dithiothreitol, 20 mM KCl, 10 mM Tris–HCl (pH 8), 30 μg/mL bovine serum albumin, and 250 ng pUC19 supercoiled DNA plasmid (MBI, Fermentas, Hanover, MD)) as previously described [36,39,41]. The immunocomplexes were detected by enhanced chemiluminescence (ECL).

**Topo I Assay**

Topo I assay was performed as previously described [26,37]. Increasing concentrations of nuclear proteins were added to a Topo I reaction mixture containing, at a final volume of 25 μL: 20 mM Tris–HCl (pH 8.1), 1 mM Dithiothreitol, 20 mM KCl, 10 mM MgCl2, 1 mM ethylenediaminetetraacetic acid (EDTA), 30 μg/mL bovine serum albumin, and 250 ng pUC19 supercoiled DNA plasmid (MBI, Fermentas, Hanover, MD). Following incubation at 37°C for 30 min, the reaction was terminated by adding 5 μL of stopping buffer (final concentration: 1% sodium dodecyl sulfate, 15% glycerol, 0.5% bromophenol blue, and 50 mM EDTA, pH 8). The reaction products were analyzed by electrophoresis on a 1% agarose gel using Tris/borate/EDTA buffer (89 mM Tris–HCl, 89 mM boric acid, and 62 mM EDTA) at 1 V/cm, stained with ethidium bromide (1 μg/mL) and photographed using a short-wavelength UV lamp (Chemilumager™ 5500 equipment, Alpha Inotech Corporation, San Leandro, CA). Densitometric analysis of the results were performed with the EZ-Quant-Gel analysis software (EZ-Quant, Rehovot, Israel), and the percentage of Topo I activity was calculated using the following equation: (1 – (sample/control)) × 100 [37].

**Immunoprecipitation Assay**

Mouse monoclonal anti-poly-ADP ribose (PAR) antibody (MCA 1490) was purchased from Serotec (Oxford, UK). Equal amounts of nuclear proteins (200 μg), which were pre-boiled for 5 min, were subjected to immunoprecipitation with anti-human Topo I antibody (SC) at a final volume of 100 μL of nuclear buffer (10 mM Tris–HCl, pH 7.4, 10 mM NaCl, 1.5 mM MgCl2, and protease inhibitors: 2 μg/mL aprotinin, 2 μg/mL leupeptin, 1 μg/mL pepstatin A, 2 μg/mL antipain, 100 μg/mL PMSF). The mixture was rotated at 4°C overnight. Protein A-Sepharose (0.1 g/mL) in TE buffer (10 mM Tris–HCl, pH 8, 1 mM EDTA) was added for an additional 1 h. The samples were centrifuged at 10,000 × g for 2 min and the beads were washed three times with TE buffer. The pellet was resuspended in 25 μL of sample buffer (final concentration: 7.5% glycerol, 1% SDS, 50 mM Tris–HCl, pH 6.8, 2.5% ⧤mercaptoethanol, and 0.025% bromophenol blue), boiled for 5 min, and centrifuged. The samples were loaded on 7.5% SDS–PAGE, and Western blot analysis was performed using goat polyclonal IgG (C-15) anti-Topo I or anti-poly-ADP ribose (PAR) antibodies.

**Stripping of Antibodies from the Nitrocellulose Membrane**

The membrane was immersed in a stripping buffer (100 mM 2-β-mercaptoethanol, 2% SDS, and 62.5 mM Tris–HCl, pH 6.7) followed by incubation at 50°C for 30 min with occasional agitation. The membrane was washed twice with TBPS (31.25 mM NaHPO4, 12.5 mM Na2HPO4, 13.7 mM NaCl, 0.1% Tween) for 10 min at room temperature.

**Cell Cytotoxicity Assay**

Cells (5000/well, in triplicates) were infected with *M. fermentans* at 2 × 10⁷–2 × 10⁸ MOI for 6 hrs followed by treatment with 30 μM CPT or 0.01% DMSO for an additional 12, 24, or 36 hrs. Cell survival was examined using the Neutral Red assay [42].

**Statistical Analysis**

Student t-test was used to determine the significance between experimental samples and controls. P values <0.05 were considered statistically significant (*); P values <0.01 (**) and <0.005 (***) were considered highly significant.

**Results**

1. **Live *M. fermentans* Inhibits the DNA Relaxation Activity of Topo I**

The effect of live *M. fermentans* on the activity of cellular Topoisomerase I was examined in two types of cell lines: human breast cancer (MCF7) and glioblastoma (U251). Cells were infected with live *M. fermentans* at MOI of 10⁷ CFU/cell, for various intervals (1.5, 3, 6, 12, and 24 hrs). Nuclear extracts were

---

**Figure 5. PARP inhibitor prevented the Mycoplasma-induced inhibitory effect on Topo I activity.** MCF7 cells were pre-incubated with 3-aminobenzamide (3AB) for 1 hr at various concentrations followed by *M. fermentans* infection (MOI of 10⁵ CFU/cell) for an additional 6 hrs. Total nuclear protein (12.5 ng) was added to a specific reaction mixture for Topo I. Reaction products were analyzed by agarose gel electrophoresis (A) and quantification of Topo I activity was performed (B). Symbols: R and S are the relaxed and supercoiled form of the pUC19 DNA, respectively, Topo- no protein added to the reaction mixture 5-t test: *p*<0.05, **p**<0.01, ***p***<0.005.

DOI: 10.1371/journal.pone.0072377.g005

---

Nucleic Acid Research (NAR)
prepared from infected and uninfected cells and Topo I activity was measured. Equivalent amounts of nuclear extract proteins were added to a Topo I DNA relaxation assay mixture containing supercoiled DNA plasmid as the substrate for the enzyme; the reaction products were analyzed by agarose gel electrophoresis. Topo I activity is measured by the conversion of supercoiled plasmid to its partially or fully relaxed forms [19]. Both cell types infected by *M. fermentans* demonstrated a significant decrease, up to 80%, in the DNA relaxation activity of the enzyme, compared to uninfected cells. A gradual decrease in Topo I activity was observed starting 1.5 hr after infection with *M. fermentans*, and the peak of the reduction in the enzyme activity (80%) was detected at 6 hrs post-infection. Significant reduction in the DNA relaxation activity of Topo I was also detected 12 and 24 hrs post-infection (30–50% for MCF7, 25–40% for U-251, respectively) (Figure 1A–D). However, the degree of the reduction in Topo I activity decreased with time, suggesting that the effectiveness of the signal mediated by Mycoplasma is weakened, as was previously demonstrated for Mycoplasma-mediated signal transduction pathways [31,43]. To confirm that the cells were actually infected and the observed effect is due to the presence of *M. fermentans*, we assayed the presence of Mycoplasma DNA in the infected cells by reverse transcriptase polymerase chain reaction (RT-PCR) assay using *M. fermentans*-specific primers. The results confirmed that the examined tumor cell lines were indeed infected with *M. fermentans* (Figure 2A).

To examine whether the decrease in Topo I activity in infected tumor cells is a consequence of a reduction in Topo I protein level, nuclear extracts derived from both infected and uninfected cells were analyzed by Western blot with the appropriate anti-Topo I antibodies. As depicted in Figure 2C–F, the level of Topo I protein in infected cells was similar to that found in uninfected cells. The results suggest that the reduction in Topo I activity was not due to a decrease in the enzyme protein amount.

**2. Inhibition of the DNA Relaxation Activity of Topo I by Sonicated *M. fermentans***

To determine whether the Mycoplasma effect on Topo I is exerted by materials secreted from live Mycoplasma or by structural proteins of this bacteria, we examined Topo I activity in tumor cells treated with non-live, sonicated, *M. fermentans*. Cells (MCF7 and U251) were treated for 24 hrs with increasing protein concentration (5, 10, and 20 µg/ml) derived from sonicated *M. fermentans*. Nuclear extract was prepared from the treated and untreated cells and Topo I DNA relaxation activity was measured. As shown in Figure 3A,D, a significant reduction in Topo I activity was observed, in a dose-dependent manner, in cells treated with *M. fermentans* proteins (sonicate). Quantification of Topo I activity [37] from multiple experiments (n = 4) was performed. A reduction of 40–60% (p<0.05) in Topo I activity is observed in cells treated with 5–20 µg/ml of sonicated *M. fermentans* proteins for 24 hrs (Figure 3B,E). Although reduction of Topo I activity in cells treated with sonicated Mycoplasma was observed, the level of Topo I protein was not affected (Fig. 3C,F).
This result indicates that either live or non-live (sonicated) *M. fermentans* exerted similar effects on the cellular Topo I enzyme.

3. *M. fermentans* Diminished the CPT Inhibition Effect on the DNA Relaxation Activity of Topo I

It was of interest to examine the effect of Mycoplasma infection on the inhibitory ability of known Topo I antagonists such as CPT. Initially, we conducted a series of experiments in which cells were treated with various concentrations of CPT in order to select the CPT dose that causes nearly full inhibition of the enzyme activity within a short period of time (not shown). We selected a CPT dose of 30 μM, which inhibited Topo I activity by 90–95% within 1.5 h (Figure 4A,B; compare lane 4 to lane 2). Cells were infected with live *M. fermentans* for 6 hrs at MOI of 10^3 CFU/cell, followed by 30 μM CPT treatments for an additional 1.5 hrs. A significant diminishing in the CPT inhibitory effect (from 95% inhibition to approximately 60%) was observed in MCF7 cells exposed to the combination of *M. fermentans* infection and CPT treatment (Figure 4A,B, compare lane 6 to lane 4, p<0.005). Similar results were obtained with U251 cells (Figure S1 A–B). Treatment of cells with CPT is known to reduce the quantity of free Topo I protein present in the nucleoplasm due to the stabilization of the enzyme–DNA cleavable complexes by CPT. Indeed, treatment of tumor cells with CPT reduced the level of free Topo I protein (Figure 4C lane 3). The combination of Mycoplasma infection and CPT treatment did not affect the level of free Topo I protein when examined relative to the amount of β-actin protein (Figure 4C).

4. Poly (ADP-ribose) Polymerase (PARP) Antagonists Prevented the Mycoplasma-induced Inhibitory Effect on Topo I Activity

The aforementioned results suggest that the reduction in Topo I activity in tumor cells exerted by *M. fermentans* might be due to post-translational modifications of the enzyme proteins. Topo I undergoes several post-translational modifications, which affect its activity: Phosphorylation of Topo I by Casein kinase II or by PKC increases its activity, whereas Poly-ADP ribosylation by PARP-1 decreases its activity. In addition, ubiquitination of Topo I leads to its proteolysis [44,45]. To determine the pathway by which *M. fermentans* affects topoisomerase I, we first investigated the effect of poly (ADP-ribose) polymerase (PARP) inhibitor –3-aminobenzamidine (3AB) on Topo I activity, alone and as a pre-treatment to *M. fermentans* infection. MCF7 cells were pre-incubated with 3AB at different concentrations (1–3 mM) for 1.5 hrs followed by *M. fermentans* infection (MOI of 10^3 CFU/cell) and incubation for an additional 6 hrs. Nuclear extract was prepared and analyzed for Topo I activity as described above. The results depicted in Figure 5A–B show that pretreatment with 3AB prevented the *M. fermentans*-induced reduction in Topo I activity. Treatment of uninfected cells with 3AB for the indicated time did not influence the cellular Topo I activity (Figure 5A,B). Similar results were obtained with the U-251 cells (Figure S2 A–B).

5. MEK Inhibitor Prevented the Mycoplasma-induced Reduction in Topo I Activity and ERK 1/2 Phosphorylation

Recent reports demonstrated that PARP-1 is phosphorylated by ERK [28]. The effect of live *M. fermentans* on MAPKs in general was not thoroughly studied. Most of the studies regarding *M. fermentans* infection increased Poly-ADP-ribosylation (PAR) of Topo I derived from MCF7 cells. Nuclear protein extracts (200 μg) derived from *M. fermentans* infected and uninfected cells were subjected to immunoprecipitation with SC-anti-Topo I antibody. (A) The immuno complexes were analyzed by Western blotting with either anti-Topo I or anti-PAR antibodies. (B) Quantification analysis of Poly ADP ribosylated Topo I derived from MCF7 extracts. *Indicates t-test value of p<0.05.

doi:10.1371/journal.pone.0072377.g007

Figure 7. *M. fermentans* infection increased Poly-ADP-ribosylation (PAR) of Topo I derived from MCF7 cells. Nuclear protein extracts (200 μg) derived from *M. fermentans* infected and uninfected cells were subjected to immunoprecipitation with SC-anti-Topo I antibody. (A) The immuno complexes were analyzed by Western blotting with either anti-Topo I or anti-PAR antibodies. (B) Quantification analysis of Poly ADP ribosylated Topo I derived from MCF7 extracts. *Indicates t-test value of p<0.05.
Topo I activity (Figure 6A, B), and in contrast, treatment of cells with the inhibitor (PD) prevented the *M. fermentans*-induced reduction in Topo I activity (Figure 3A,B for U-251 cells). In addition, we found that the quantity of p-ERK1/2 increased in infected cells (Figure 6C for MCF7 cells and Figure S3 C for U-251) while pre-treatment with PD prevented this increase. The level of total ERK was not affected by the various treatments (Figure 6C). These results suggest that the reduction in Topo I activity in *M. fermentans*-infected cells is mediated by MAPK signaling.

6. *M. fermentans* Infection Increased Poly-ADP-ribosylation of Topo I Derived From MCF7 Cells

PARP-1 regulates Topo I activity by ADP-ribosylation of the enzyme protein [46]. To examine whether infection with *M. fermentans* induced Topo I modification by PARP, Topo I protein was immunoprecipitated by anti-Topo I antibodies derived from scleroderma (SC) patient serum [47] and analyzed by Western blot using anti-Poly-ADP-ribose monoclonal antibody (Figure 7A). A protein of 100 kDa was immunoprecipitated by anti-Topo I antibody SC serum, and reacted (in Western blot assay) with anti-Poly-ADP-ribose antibody (Figure 7A-left panel) and with goat polyclonal IgG anti-Topo I antibody, confirming the identification of the ADP-ribosylated Topo I. An increase in the level of Poly-ADP-ribosylation of Topo I in the *M. fermentans*-infected MCF7 cells (up to 160±20%, *p<0.05*) was observed in comparison to the uninfected cells (Figure 7B, *n* = 3 independent experiments).

7. Infection of Tumor Cells with *M. fermentans* Prior to CPT Treatment Reduced the Anti-cancer Efficacy of CPT

MCF7 cells were infected with *M. fermentans* for 6 hrs at MOI of 2×10^3 followed by CPT (30 μM) treatment for 12, 24, and 36 hrs. Cell viability was examined and the percent of cell viability relative to the treatment’s control was calculated. As described in Figure 6, pretreatment of the cells with Mycoplasma significantly decreased the cytotoxic level of CPT. An increase of 24±7.5% and 31±4.7% in cell survival (compared to the appropriate control of Mycoplasma-infected cells) was established 24 and 36 hrs, respectively, after CPT treatment. The results suggest that the infection of tumor cells with Mycoplasma altered the anti-cancer efficacy of CPT.

Discussion

The efficacy of an anti-cancer drug depends on many cellular and environmental factors, of which a crucial one is the functionality of the target of the drug. Since Mycoplasma infect cells, including tumor cells, and this infection was previously shown to modify cell signaling [11–13,17], we examined the influence of *M. fermentans* strain K7 on an essential anti-cancer drug target, the cellular DNA Topoisomerase I, and the effect of this infection on its inhibitor Camptothecin (CPT), the derivatives of which are currently in clinical use as anti-cancer drugs.

The results show, for the first time, that infection with live *M. fermentans* of breast cancer (MCF7) and glioblastoma brain tumor (U-251) cells line significantly reduced (by 80%) the activity of cellular Topo I. This reduction was also observed when non-live (sonicated) Mycoplasma was used instead of live Mycoplasma, suggesting that the effect on cellular Topo I is probably mediated by Mycoplasma surface proteins/glycoproteins. The reduction in Topo I activity was detected 1.5 hrs after cell infection with *M. fermentans*, suggesting that Topo I is modified at early stages of the infection. The maximum reduction in Topo I (80%) was detected 6 hrs after infection, and a significant decrease in the enzyme activity, alone or prior to infection with *M. fermentans*. MCF7 and U-251 cells were pre-incubated with PD for 1.5 hrs at a concentration of 25 μM followed by *M. fermentans* infection (MOI of 10^3 CFU/cell) and incubation for an additional 6 hrs. Nuclear extract was prepared and analyzed for Topo I activity and phosphorylation of ERK using Western blot analysis with specific anti p-ERK 1/2 antibody. The results demonstrated that the addition of MEK inhibitor to the Topo I reaction did not affect the results. 

Figure 6. Infection of MCF7 cells with *M. fermentans* prior to CPT treatment altered the cytotoxic effect of CPT. MCF7 cells (5000/well) were infected with *M. fermentans* (MOI 2×10^3) for 6 hrs followed by CPT treatment for 12 (A), 24 (B), or 36 (C) hrs. Cell cytotoxicity was examined by the Neutral Red assay. The Y-axis demonstrates the percent of cell survival calculated as follows: [%cell survival in infected MCF7 cells (up to 160±20%, *p<0.05*) was observed in comparison to the uninfected cells (Figure 7B, *n* = 3 independent experiments).

**Discussion**

The efficacy of an anti-cancer drug depends on many cellular and environmental factors, of which a crucial one is the functionality of the target of the drug. Since Mycoplasma infect cells, including tumor cells, and this infection was previously shown to modify cell signaling [11–13,17], we examined the influence of *M. fermentans* strain K7 on an essential anti-cancer drug target, the cellular DNA Topoisomerase I, and the effect of this infection on its inhibitor Camptothecin (CPT), the derivatives of which are currently in clinical use as anti-cancer drugs.

The results show, for the first time, that infection with live *M. fermentans* of breast cancer (MCF7) and glioblastoma brain tumor (U-251) cells line significantly reduced (by 80%) the activity of cellular Topo I. This reduction was also observed when non-live (sonicated) Mycoplasma was used instead of live Mycoplasma, suggesting that the effect on cellular Topo I is probably mediated by Mycoplasma surface proteins/glycoproteins. The reduction in Topo I activity was detected 1.5 hrs after cell infection with *M. fermentans*, suggesting that Topo I is modified at early stages of the infection. The maximum reduction in Topo I (80%) was detected 6 hrs after infection, and a significant decrease in the enzyme activity, alone or prior to infection with *M. fermentans*. MCF7 and U-251 cells were pre-incubated with PD for 1.5 hrs at a concentration of 25 μM followed by *M. fermentans* infection (MOI of 10^3 CFU/cell) and incubation for an additional 6 hrs. Nuclear extract was prepared and analyzed for Topo I activity and phosphorylation of ERK using Western blot analysis with specific anti p-ERK 1/2 antibody. The results demonstrated that the addition of MEK inhibitor to the Topo I reaction did not affect the results.
activity (40%) was still observed 24 hrs after infection, indicating continuous modifications of Topo I activity in the presence of live or sonicated Mycoplasma. To understand the mechanism by which Mycoplasma infection reduced Topo I activity, several parameters were examined. First we showed that the reduction in Topo I DNA relaxation activity was not a consequence of a decrease in the enzyme protein level; thus, M. fermentans infection did not alter the expression of Topo I. Second, the effect of Mycoplasma infection on Topo I inhibition by CPT was examined. The results indicate that the level of inhibition of the Topo I DNA relaxation activity was reduced in infected cells by 4-fold compared to CPT-treated uninfected cells. Depletion in the free Topo I enzyme in the nucleoplasm of CPT-treated cells is a known phenomenon of CPT inhibition, which is a consequence of CPT-induced stabilization of the cleavable DNA-enzyme complex [21,24,25]. In Mycoplasma-infected cells, this Topo I depletion was partially diminished, implying that the enzyme protein was modified in the infected cells and this modification affected the enzyme-DNA interaction. Since infection with M. fermentans reduced the activity of cellular Topo I without affecting its protein level, it is reasonable to propose that M. fermentans infection of the tumor cells caused post-translational modifications of Topo I protein, reducing its activity. Topo I protein is known to undergo several post-translational modifications that influence its activity, such as phosphorylation of serine threonine residues, which is essential for its DNA relaxation activity, while dephosphorylation will reduce it. ADP-ribosylation of Topo I protein by PARP-1, as well as phosphorylation of tyrosine residues in the active site of the enzyme, are known to inhibit the DNA relaxation activity of Topo I [20,27]. GlcNacylation of the enzyme protein was shown by us to affect the DNA relaxation activity of Topo I [26]. Therefore, to elucidate which of the aforementioned modifications may occur in M. fermentans-infected cells, we first examined the modification that reduced Topo I activity, namely ADP-ribosylation of the enzyme protein by PARP-1. The results revealed that treatment of cells with PARP-1 inhibitors prior to Mycoplasma infection totally diminished the Mycoplasma-induced reduction in Topo I DNA relaxation activity, suggesting that PARP-1 activation is involved in this process. To examine if Mycoplasma infection indeed induced PARP-1 activation, we looked for relevant signal transduction pathways that are induced in cells following Mycoplasma infection. It was previously shown that various MAPKs (i.e., SAPK/JNK, p38, NF-kB, AP-1, and ERK 1/2) were activated following the treatment of cells with lipid-associated Mycoplasma proteins (LAMP) [11,29–31].

Unrelated to Mycoplasma infection, it was shown that PARP-1 is activated by ERK and its activity is up-regulated by ERK-catalyzed phosphorylation [28]. In this study, we have demonstrated that infection of cells with M. fermentans induced the phosphorylation of ERK1/2, which was prevented when MEK inhibitor was administered prior to cell infection. The notion that the decrease in Topo I activity in Mycoplasma-infected cells is mediated by the ERK signaling pathway was also demonstrated, since pre-incubation of the cells with MEK inhibitor prevented the Mycoplasma-induced decrease in Topo I activity. Moreover, we also demonstrated that in Mycoplasma-infected cells an increase in ADP-ribosylation of Topo I protein was observed.

Since Topo I is the target of the camptothecins, which are potent anti-cancer agents, the enzyme modification and the reduction in its activity may influence the efficacy of this anti-cancer drug in tumor cells that are infected with Mycoplasma. Indeed, we demonstrate that infection of MCF7 cells with M. fermentans prior to CPT treatment significantly decreased the cytotoxic effect of CPT. However, since we previously showed that CPT inhibited Mycoplasma growth [Horowitz, 1997 #55], it is also possible that the alteration in CPT efficacy is also due to the consumption of CPT by Mycoplasma.

In summary, we believe that the pathway by which infection of cells with M. fermentans decreases the DNA relaxation activity of Topo I is via the induction of the MAPK signaling pathway in which ERK1/2 is phosphorylated by MEK. As illustrated in Figure 9, the p-ERK activates PARP-1, which modifies Topo I protein by ADP-ribosylation, decreasing the ability of Topoisomerase I to relax supercoiled DNA. Our data also suggest that this ADP ribosylation of Topo I interfered with its ability to bind DNA as demonstrated by the diminished inhibition of Topo I by CPT treatment in Mycoplasma-infected cells.
In conclusion, infection of tumor cells with Mycoplasma induced signal transduction pathways (i.e., the MAPK pathway including ERK2 and PARP-1) that can cause modifications of essential cellular enzymes such as Topo I and affect their activity. Moreover, the enzyme modification and the reduction in its activity influence the efficacy of its inhibitor as an anti-cancer drug. It is not yet clear if Mycoplasma infection of tumors occurs in vivo in patients, but our data clearly indicate that this possibility should be considered, specifically when anti-Topo I drugs are administered.

Supporting Information

Figure S1 M.fermentans diminished the CPT inhibition effect on the DNA relaxation activity of topo I. U251 cells were infected with M.fermentans (Mf) for 6 hrs., followed by CPT (30 µM) treatments for additional 1.5 hrs. Total nuclear protein (12.5 ng) was added to a specific reaction mixture for Topo I. Reaction products were analyzed by agarose gel electrophoresis (A) a representative picture n = 3, of Topol DNA-relaxation activity. B: Quantification analysis of Topol activity. Symbols: R and S are the relaxed and supercoiled form of the pUC19 DNA respectively, Topo- :no protein added to the reaction mixture. t-test: *p<0.05, **p<0.01, ***p<0.005 (TIF)

Figure S2 PARP inhibitor prevented the mycoplasma-induced inhibitory effect on topo I activity. U251 cells were pre-incubated with 3-aminohenzamide (3AB) for 1 hour at various concentrations followed by M.fermentans (Mf) infection (MOI of 10^3 CFU/cell) for additional 6 hrs. Total nuclear protein (12.5 ng) was added to a specific reaction mixture for Topo I. Reaction products were analyzed by agarose gel electrophoresis (A) and quantification of topo I activity was performed (B). Symbols: R and S are the relaxed and supercoiled form of the pUC19 DNA respectively, Topo- :no protein added to the reaction mixture. t-test: *p<0.05, **p<0.01, ***p<0.005 (TIF)

Acknowledgments

We thank Liraz Gold, Fabian Afergan, Elena Robinstein, Orly Sagi, and Frida Inghel from the mycoplasma laboratory, Soroka University Medical Center, Beer-Sheva, Israel, for technical assistance; and Refael Peleg for helpful remarks.

Author Contributions

Conceived and designed the experiments: RA SH EP. Performed the experiments: RA. Analyzed the data: RA SH EP. Contributed reagents/materials/analysis tools: EP. Wrote the paper: RA SH EP.

References

1. Razin S, Yogev D, Naot Y (1998) Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 62: 1094–1156.
2. Rotten S (2003) Interaction of mycoplasmas with host cells. Physiol Rev 83: 417–432.
3. Razin S, Yogev D, Naot Y (1998) Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 62(4): 1094–1136.
4. Horowitz S, Evinson B, Borer A, Horowitz J (2000) M. fermentans in rheumatoid arthritis and other inflammatory arthritides. J Rheumatol 27: 2747–2753.
5. Baseman JB, Lange M, Cricimagna NL, Giron JA, Thomas CA (1995) Interplay between mycoplasmas and host target cells. Microb Pathog 19: 103–116.
6. Tsai S, Wear DJ, Shih JW, Lo SC (1995) Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci U S A 92: 10197–10201.
7. Feng SH, Tsai S, Rodriguez J, Lo SC (1995) Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 3D hematopoietic cells. Mol Cell Biol 15: 7995–8002.
8. Jiang S, Zhang S, Langenfeld J, Lo SC, Rogers MB (2007) Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by posttranscriptional mechanisms. J Cell Biochem 104: 580–594.
9. Namki K, Goodson S, Povsavnik S, Allan RW, Iczkowski KA, et al. (2009) Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One 4: 6872.
10. Rogers MB (2011) Mycoplasma and cancer: in search of the link. Oncotarget 2: 271–273.
11. Rawadi G, Zugaza JL, Lemercier JC, Popoff M, et al. (1999) Involvement of small GTPases in Mycoplasma fermentans-induced membrane lipoproteins-mediated activation of macrophages. J Biol Chem.
12. Sugama K, Kusunou K, Furukawa M, Himeno Y, Sato T, et al. (1990) Mycoplasma induces transcription and production of tumor necrosis factor in a monocytic cell line, THP-1, by a protein kinase C-independent pathway. Infect Immun 58: 3564–3567.
13. Marie C, Roman-Roman S, Rawadi G (1999) Involvement of mitogen-activated protein kinase pathways in interleukin-1 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Infect Immun 67: 688–693.
14. Dong L, Shihata K, Sawa Y, Hasebe A, Yamaoka Y, et al. (1999) Transcriptional activation of mRNA of intercellular adhesion molecule 1 and induction of its cell surface expression in normal human gingival fibroblasts by Mycoplasma salivarium and Mycoplasma fermentans. Infect Immun 67: 3061–3065.
15. Shihata K, Watanabe T (1997) Mycoplasma fermentans enhances concanavalin A-induced apoptosis of mouse splenic T cells. FEMS Immunol Med Microbiol 179–229.
16. Shave-Huey Feng SC, GL (1999) Lipid Extract of Mycoplasma fermentans Protease K-Digested Lipid-Associated Membrane Proteins Rapidly Activates NFκB and Activator Protein 1. Infect Immun 67(6): 2951–2956.
17. Gerlic M, Horowitz J, Farkash S, Horowitz S (2007) The inhibitory effect of Mycoplasma fermentans on tumor necrosis factor (TNF)-alpha-induced apoptosis resides in the membrane lipoproteins. Cellular Microbiology 9(1): 142–153.
18. Gerlic M, Horowitz J, Horowitz S (2004) Mycoplasma fermentans inhibits tumor necrosis factor alpha-induced apoptosis in the human myelomonocytic U937 cell line. Cell Death Differ 11: 1204–1212.
19. Pommier Y, Pourquier P, Fan Y, Smunenkov D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochimica et Biophysica Acta - Gene Structure and Expression 1400: 83–106.
20. Cretaio E, Pattarello L, Fontebasso Y, Benedetti P, Losasso C (2007) Human DNA topoisomerase IB: structure and functions. Ital J Biochem 56(2): 91–102.
21. Tomicic MT, Kaina B (2013) Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1835: 11–27.
22. Champoux JJ (2001) DNA topoisomerases: structure, function and mechanism. Biochem 70: 369–413.
23. Wang JC (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 3: 430–440.
24. Pommier Y BJ, Rao VA, Sordet O, Jobson AG, Thibaut L, et al. (2006) Repair Modification of Topoisomerase I by Glucose and by O-Glcnacylation of the Enzyme. Biochimica et Biophysica Acta (BBA) - Protein Glycobiology 17: 1357–1364.
27. Homburg S, Visochek L, Moran N, Dantzer F, Priel E, et al. (2000) A Fast Signal-induced Activation of Poly(ADP-ribose) Polymerase: A Novel Downstream Target of Phospholipase C. J Cell Biol 150: 293–308.
28. Cohen-Armon M, Visochek L, Rosemaï D, Kalal A, Geissrikh I, et al. (2007) DNA-Independent PARP-1 Activation by Phosphorylated ERK2 Increases Elk1 Activity: A Link to Histone Acetylation. Molecular Cell 25: 297–308.
29. Gong MM, Meng L, Jiang B, Zhang J, Yang H, et al. (2008) p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR. Mol Cancer Ther 7: 530–537.
30. Yang H, Qu L, Ma H, Chen L, Liu W, et al. (2010) Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol 10: 132.
31. You X, Wu Y, Zeng Y, Deng Z, Qiu H, et al. (2008) Mycoplasma genitalium-derived lipid-associated membrane proteins induce activation of MAPKs, NF-kB and AP-1 in THP-1 cells. FEMS Immunology & Medical Microbiology 52: 229–236.
32. Lennette EH, Balows A, Hausler Jr WJ, Truant JP, Kenny GE (1980) Mycoplasma. Manual of clinical microbiology Washington, D.C.: American Society for Microbiology. 365–370.
33. Razin S, Tully JG (1983) General cultivation techniques for Mycoplasmas and Spiroplasmas. NY, NY: Academic Press Inc. 99–102 p.
34. Wang RY, Hu Ws, Dawson MS, Shin Jw, Lo SC (1992) Selective Detection of Mycoplasma fermentans by Polymerase Chain Reaction and by Using a Nucleotide Sequence within the Insertion Sequence-Like Element. J Clin Microbiology 30: 245–249.
35. Auer B, Vosberg H, Buhre U, Klocker H, Hirsch-Kauffmann M, et al. (1982) Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi’s anemia. Hum Genet: 369–371.
36. Sambrook J, Fritch E, Maniatis T (1989) Molecular cloning: A laboratory manual.; Sambrook J, Fritch E, Maniatis T, editors. NY: Cold Spring Harbor Laboratory.
37. Bendets-Nezer S, Gazit A, Priel E (2004) DNA Topoisomerase Las One of the Cellular Targets of Certain Tyrophostin Derivatives. Mol Pharmacol 66: 627–634.
38. Noach N, Segov Y, Levi I, Segal S, Priel E (2007) Modification of topoisomerase I activity by glucose and by O-GlcNAcylation of the enzyme protein. Glycobiology 17: 1357–1364.
39. Levi I, Segov Y, Priel E (2012) Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: Kidney, liver and pancreas Glycobiology 22(5): 704–713.
40. Stewart L, Champoux JJ (2001) Assaying DNA topoisomerase I relaxation activity. In: Osheroff N, Bjornsti MA, editors. Methods in Molecular Biology: DNA topoisomerase Protocols. Totowa, New Jersey, USA: Humana Press Inc. 1–11.
41. Kaufmann S, Svingen P (1999) Immunoblot analysis and band depletion assays.; Bjornsti MA, Osheroff N, editors. Totowa, NJ: Humana Press Inc.
42. Johnston M, Finter N, Young P (1981) Dye uptake method for assay of interferon activity. Methods Enzymol 78: 394–399.
43. Yang H, Qu L, Ma H, Chen L, Liu W, et al. (2010) Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol 10: 132.
44. Desai S, Li T, Rodriguez-Bauman A, Rubin E, Liu L (2001) Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61: 5926–5932.
45. Desai S, Zhang H, Rodriguez-Bauman A, Yang JM, Wu X, et al. (2003) Transcription-dependent degradation of topoisomerase-I-DNA covalent complexes. Mol Cell Biol 23: 2341–2350.
46. Park S-Y, Cheng Y-C (2005) Poly (ADP-ribose/polymerase-1 could facilitate the religation of topoisomerase-I linked DNA inhibited by camptothecin. Cancer Res 65: 3894–3902.
47. Shero JH, Bordwell B, Rohrfield NF, Earnshaw WC (1986) High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231: 737–740.